AI주식인사이트AI Stock Insight
C

영진약품

003520KOSPI의약품 제조업

41.1 / 100

Reference Date: 2026-07-24

Financial Score8.0 / 40
News Sentiment18.1 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Youngjin Pharmaceutical, a core subsidiary of KT&G Group, has built trust through awards such as the Presidential Award and focuses on enhancing national health and the pharmaceutical industry. In 2025, it achieved sales of 2.543 trillion KRW and an operating profit of 34 billion KRW, strengthening its domestic market position and diversifying exports globally. It is driving growth through R&D investment and ESG management to solidify its position as a global pharmaceutical company.

Number of Employees

626people

Average Salary

69.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.234.0Point
PBR
2.42Industry Average 0.810.0Point

3.0x industry avg (risky)

ROE
-0.25Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
79.18Industry Average 12.430.0Point

6.4x industry avg (risky)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲4.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲59.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.1% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 1Negative 1Average Sentiment Score 72.5

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 1,210Won52-week high 2,20052-week low 1,105
1-month return3.0Point

1m 0.41% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0